Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

26.05USD
22 Nov 2017
Change (% chg)

$1.50 (+6.11%)
Prev Close
$24.55
Open
$24.70
Day's High
$26.60
Day's Low
$24.70
Volume
92,994
Avg. Vol
41,332
52-wk High
$28.65
52-wk Low
$15.95

Select another date:

Mon, Nov 20 2017

BRIEF-Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

* Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

BRIEF-Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01

* Revance Therapeutics Inc - ‍sakura 1 & 2 phase 3 pivotal trials on track to report topline results before year-end 2017​

BRIEF-Revance completes patient enrollment in Phase 2 program for RT002 injectable

* Revance completes patient enrollment in Phase 2 program for RT002 injectable in the management of plantar fasciitis

BRIEF-Revance Q2 ‍loss per share $0.90​

* Revance Therapeutics Inc - ‍reaffirmed its financial guidance provided in January 2017​

BRIEF-Revance Therapeutics updates on phase 2 clinical trial results

* Positive Belmont phase 2 trial results published in dermatologic surgery

BRIEF-Revance reports additional positive week 24 efficacy results from rt002 injectable phase 2 cervical dystonia trial

* Revance reports additional positive week 24 efficacy results from rt002 injectable phase 2 cervical dystonia trial

Select another date: